<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>HIV Management on FinanClub</title>
    <link>https://finan.club/tags/hiv-management/</link>
    <description>Recent content in HIV Management on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Sat, 16 Mar 2024 09:09:30 +0000</lastBuildDate><atom:link href="https://finan.club/tags/hiv-management/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>IBRX</title>
      <link>https://finan.club/us/ibrx/</link>
      <pubDate>Sat, 16 Mar 2024 09:09:30 +0000</pubDate>
      
      <guid>https://finan.club/us/ibrx/</guid>
      <description>score:157
Chances: The recent publication of preclinical data in the online issue of Science, First Release is a positive indication of the potential of ImmunityBio&amp;rsquo;s combination therapy with N-803 and broadly neutralizing antibodies for managing HIV without the need for antiretroviral treatment. Risks: The company&amp;rsquo;s therapies are still in clinical stage, indicating that there is a risk of failure or delays in development.</description>
    </item>
    
  </channel>
</rss>
